A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy

Citation for published version (APA):

Lambrechts, D. A. J. E., de Kinderen, R. J. A., Vles, J. S. H., de Louw, A. J., Aldenkamp, A. P., & Majoie, H. J. M. (2017). A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy. *Acta Neurologica Scandinavica*, 135(6), 678-678. <https://doi.org/10.1111/ane.12737>

DOI:

[10.1111/ane.12737](https://doi.org/10.1111/ane.12737)

Document status and date:

Published: 01/06/2017

Document Version:

Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.tue.nl/taverne

Take down policy

If you believe that this document breaches copyright please contact us at:

openaccess@tue.nl

providing details and we will investigate your claim.

A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy

Response to Letter-to-the-Editor

We would like to thank Dr. Almomen and Dr. Burton for their interest in our article.¹

We fully agree that the distribution of the etiologic category genetic and structural is uneven between the ketogenic diet (KD) group and the care as usual group (CAU; the control group). The program used for randomization was not stratified by etiology of the epilepsy nor for the syndrome classification. Patients were stratified according to age (1-6 years, 7-12 years, and 13-18 years), having a percutaneous gastrostomy tube or not, and whether the child is living at a residential center or attends the epilepsy center as an outpatient while he/she lives at home. The study was designed as an RCT-based economic evaluation among children and adolescents referred to our tertiary referral center for epileptology. The study did not intend to focus on a particular type of refractory epilepsy and both the MCT ketogenic diet as the classical ketogenic diet was accepted.

At the time the study protocol was written, there was substantially less information on syndrome specific effectiveness of the KD. Furthermore, currently it is still not possible to predict good responders, except for the glut-1 deficiency syndrome and pyruvate dehydrogenase complex deficiency.

Taking into account the syndromes, of which there is most information of cohort studies at present, the difference in number of included patients in both groups is not extremely different (West syndrome: N=3 in KD group and N=2 in CAU, Dravet syndrome: N=1 in KD group and N=0 in control group, Lennox-Gastaut syndrome: N=1 in KD group and N=0 in CAU, and finally, Doose syndrome: N=3 in KD group and N=2 in CAU group).

We did perform a logistic regression analysis. There was no variable (including etiology of the epilepsy and syndrome classification or age at ketogenic diet initiation) with a statistically significantly influence on being a responder or not.

Patients aged between one and eighteen years old were included, which is a wide age range. In our opinion, this has not caused any major problem in terms of dietary compliance or seizure documentation. Ketosis, which is an indicator for compliance, was measured frequently. Ketosis was checked daily by the parents in urine or three times a week in blood via a finger puncture. The largest challenge with compliance can be expected in teenagers, which was the smallest group in our cohort; 27% was younger than 5 years and another 50% was younger than 10 years. Parents and caregivers were responsible for good seizure documentation. This was necessary because of the age distribution of the cohort and the fact that half of the children had an IQ <70. The reliability of the use of seizure diaries in clinical

research is a shared concern, although it is accepted and as yet no alternative is available, especially for long-term follow-up.

Given the nature of the intervention, it is not possible to reach the golden standard of a placebo-controlled double-blinded trial. But in our opinion, this has not biased the adjustments in antiepileptic drug (AED) dose. The percentages mentioned in the table with demographic and clinical characteristics are the percentage of patients with no changes in AED dose. The adjustment of AED dose occurred more frequently in the CAU group. At 4 months, two children in the KD group had an increase and one child a decrease in the dose of one AED. In the CAU group, three children had a dose increase in one AED and two children a dose increase in one AED combined with a dose decrease in another AED.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interests.

D. A. J. E. Lambrechts¹

R. J. A. de Kinderen^{2,3,4}

J. S. H. Vles^{1,2,5}

A. J. de Louw^{1,6}

A. P. Aldenkamp^{2,5,6,7}

H. J. M. Majoie^{1,2,5}

¹Department of Neurology, Academic Center for Epileptology
Kempenhaghe & Maastricht UMC+, Heeze, The Netherlands

²Research School of Mental Health & Neuroscience, Maastricht
University, Maastricht, The Netherlands

³Department of Health Services Research, CAPHRI School for Public
Health & Primary Care, Maastricht University, Maastricht, The
Netherlands

⁴Department of Research & Development, Academic Center for
Epileptology Kempenhaghe & Maastricht UMC+, Heeze, The
Netherlands

⁵Department of Neurology, Maastricht University Medical Center,
Maastricht, The Netherlands

⁶Faculty of Electrical Engineering, University of Technology, Eindhoven,
The Netherlands

⁷Department of Behavioral Sciences, Academic Center for Epileptology
Kempenhaghe & Maastricht UMC+, Heeze, The Netherlands

REFERENCE

1. Lambrechts DA, de Kinderen RJ, Vles JS, de Louw AJ, Aldenkamp AP, Majoie HJ. *Acta Neurol Scand*. 2017;135:231–239.